Jefferies Group LLC Ascendis Pharma A/S Transaction History

Jefferies Group LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$78.08 - $117.61 $140,544 - $211,698	-1,800 Closed	0 $0
Q1 2022 Sep 21, 2023	BUY	$102.18 - $135.75 $183,924 - $244,350	1,800 New	1,800 $211,000
Q1 2022 May 16, 2022	BUY	$102.18 - $135.75 $183,924 - $244,350	1,800 New	1,800 $211,000
Q3 2019 Nov 13, 2019	SELL	$95.8 - $118.9 $931,080 - $1.16 Million	-9,719 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$107.11 - $132.09 $1.01 Million - $1.24 Million	9,419 Added 3139.67%	9,719 $1.12 Million
Q1 2019 May 15, 2019	BUY	$62.15 - $129.99 $18,645 - $38,997	300 New	300 $35,000

270

61.9M

151K

226K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $8.89B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.